Ionis Pharmaceuticals, Inc. Forecast, price target & analysts
Ionis Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Ionis Pharmaceuticals, Inc. Classifications & Recommendation:
Ionis Pharmaceuticals, Inc. Price Target
| Target Price | $55.74 |
| Price | $29.74 |
| Potential |
87.42%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 .
The average Ionis Pharmaceuticals, Inc. target price is $55.74.
This is
87.42%
register free of charge
$78.00
162.27%
register free of charge
$37.00
24.41%
register free of charge
|
|
| A rating was issued by 27 analysts: 18 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
87.42%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 705.14 | 643.04 |
| 10.48% | 8.81% | |
| EBITDA Margin | -64.26% | -88.85% |
| 52.80% | 38.28% | |
| Net Margin | -68.08% | -94.32% |
| 32.65% | 38.55% |
23 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
20 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.04 | -3.84 |
| 18.75% | 26.32% | |
| P/E | negative | |
| EV/Sales | 6.82 |
20 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
Current Ionis Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Redburn Atlantic |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Redburn Atlantic:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 24 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 11 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
